Second Sight Medical Products, Inc. (EYES)
After hours:
| Previous Close | 2.2700 |
| Open | 2.3100 |
| Bid | 2.2000 x 800 |
| Ask | 2.3400 x 1300 |
| Day's Range | 2.2700 - 2.3400 |
| 52 Week Range | 1.1400 - 5.2800 |
| Volume | |
| Avg. Volume | 351,691 |
| Market Cap | 91.823M |
| Beta (5Y Monthly) | 2.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2250 |
| Earnings Date | Jun 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®
LOS ANGELES, April 14, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States.
- Business Wire
Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company
LOS ANGELES & EMERYVILLE, Calif., February 07, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight") and Nano Precision Medical, Inc. ("NPM"), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and dev
- Business Wire
Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
LOS ANGELES, August 11, 2021--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses
